Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling of cell-free DNA

BRCA1-mutated prostate cancer has been shown to be less responsive to poly (ADP-ribose) polymerase (PARP) inhibitors as compared to BRCA2-mutated prostate cancer. The reason for this differential response is not clear. We hypothesized this differential sensitivity to PARP inhibitors may be explained...

Descripción completa

Detalles Bibliográficos
Autores principales: Swami, Umang, Zimmerman, Raquel Mae, Nussenzveig, Roberto H., Hernandez, Edgar Javier, Jo, Yeonjung, Sayegh, Nicolas, Wesolowski, Sergiusz, Kiedrowski, Lesli A., Barata, Pedro C., Lemmon, Gordon Howard, Bilen, Mehmet A., Heath, Elisabeth I., Nandagopal, Lakshminarayan, Babiker, Hani M., Pal, Sumanta K., Lilly, Michael, Maughan, Benjamin L., Haaland, Benjamin, Yandell, Mark, Sartor, Oliver, Agarwal, Neeraj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521349/
https://www.ncbi.nlm.nih.gov/pubmed/36185208
http://dx.doi.org/10.3389/fonc.2022.966534

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521349/
https://www.ncbi.nlm.nih.gov/pubmed/36185208
http://dx.doi.org/10.3389/fonc.2022.966534

Ejemplares similares